Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Bio-Gene Technology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Bio-Gene Technology şirketinin toplam hissedar öz sermayesi A$2.8M ve toplam borcu A$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$3.2M ve A$368.4K dir.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	n/a
Nakit	AU$2.21m
Eşitlik	AU$2.79m
Toplam yükümlülükler	AU$368.45k
Toplam varlıklar	AU$3.16m

Son finansal sağlık güncellemeleri

We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely

Feb 22

Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Oct 25

Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Jun 20

Recent updates

We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely

Feb 22

Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Oct 25

Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Jun 20

Bio-Gene Technology Limited (ASX:BGT) Is Expected To Breakeven In The Near Future

Apr 28

What We Learned About Bio-Gene Technology's (ASX:BGT) CEO Compensation

Jan 11

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BGT 'nin kısa vadeli varlıkları ( A$2.9M ) kısa vadeli yükümlülüklerini ( A$345.9K ) aşıyor.

Uzun Vadeli Yükümlülükler: BGT şirketinin kısa vadeli varlıkları ( A$2.9M ) uzun vadeli yükümlülüklerini ( A$22.5K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BGT borçsuzdur.

Borcun Azaltılması: BGT son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BGT şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: BGT un, serbest nakit akışı her yıl % 7.5 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Bio-Gene Technology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Recent updates

New major risk - Share price stability

New minor risk - Financial data availability

New minor risk - Share price stability

Bio-Gene Technology Limited Approves the Election of Alex Ding as Director

Bio-Gene Technology Limited Announces Resignation of Rodrigo Valencia as Joint CFO

Bio-Gene Technology Limited Announces the Appointment of Roger Mcpherson as Joint Company Secretary

Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023

New minor risk - Shareholder dilution

New major risk - Financial position

Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.019 loss in FY 2022)

Bio-Gene Technology Limited Announces Managing Director Changes

New major risk - Market cap size

Bio-Gene Technology Limited Announces Changes to the Board

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.01 loss in 1H 2022)

Bio-Gene Technology Limited Submits Application to Secure Additional IP for Qcidetm

No independent directors

Bio-Gene Technology Limited, Annual General Meeting, Nov 18, 2022

Full year 2022 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in FY 2021)

No independent directors

Bio-Gene Technology Limited Announces Positive Stored Grain Pest Results

We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Bio-Gene Technology Limited Appoints Sarah Driessens as Head of Regulatory Affairs

Bio-Gene Technology Limited announced that it has received AUD 3.04775 million in funding

Bio-Gene Technology Limited announced that it expects to receive AUD 3.21931 million in funding

Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Full year 2021 earnings released: AU$0.017 loss per share (vs AU$0.016 loss in FY 2020)

Forecast to breakeven in 2024

Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Bio-Gene Technology Limited (ASX:BGT) Is Expected To Breakeven In The Near Future

Bio-Gene Technology Limited Appoints James Joughin as Non-Executive Director of the Company and Chairman of Audit and Risk Committee, Effective 1 March 2021

Bio-Gene Technology Limited Announces Flavocide MoA Studies Confirm Target Site of Activity

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.009 loss in 1H 2020)

Bio-Gene Technology Limited Announces Positive Preliminary Results from Aquatic (Rainbow Trout) and Avian (Mallard Duck) Eco-Toxicity Studies

What We Learned About Bio-Gene Technology's (ASX:BGT) CEO Compensation

Bio-Gene Technology Limited Appoints Peter Beetham as Non- Executive Director, Effective from 21 December 2020

Bio-Gene Technology Limited Announces Changes of Directors

Full year earnings released - AU$0.016 loss per share

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin